Compare Global Payments Inc (GPN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Inovio Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $82.2 (market cap $21.46B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Global Payments Inc is far larger — about 191.3× Inovio Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.23% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| GPN | INO | |
|---|---|---|
Market Cap | $21.46B | $112.19M |
Volume | 1,482,600 | 3,201,278 |
Sector | Financials | Health |
52-Week High | $94.83 | $2.65 |
52-Week Low | $62.47 | $0.66 |
Typical Hold Time | 50 Days | 43 Days |
Enterprise Value | $39.60B | $83.51M |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.77, up 2.08% with a neutral technical signal despite bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net income margin and ROE. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains strongly bullish with a $102.75 price target.
GPN presents a mixed outlook with strong analyst support and strategic initiatives offset by profitability concerns and rising debt levels. The stock offers 24% upside to consensus targets but faces execution risks in integrating acquisitions and maintaining margin expansion amid competitive pressures in the payments technology sector.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
